Compare compounded low-dose naltrexone with FDA-approved 50 mg naltrexone tablets and extended-release injection, including evidence limits, formulation differences, opioid interactions, and questions to ask a prescriber or pharmacy.
A clinical review of emerging LDN delivery systems, novel formulations in development, ongoing trials, and the regulatory path toward FDA-approved low-dose naltrexone products.
A clinical history of low-dose naltrexone (LDN) from its 1984 FDA approval as an opioid antagonist through off-label adoption for fibromyalgia, autoimmune disease, and chronic inflammation.
A guide to discontinuing low-dose naltrexone (LDN) safely, including tapering schedules, rebound risk, mechanism of action, and what clinical evidence actually shows.
A clinician-level guide to safely restarting compounded low-dose naltrexone (LDN) after an acute illness, including when to pause, how to re-titrate, and what the evidence says about opioid receptor modulation and immune function.
Your first month of low-dose naltrexone: weekly symptom tracking, sleep and side effects, prescription checks and the month-one treatment review.
Naltrexone can trigger acute opioid withdrawal at any dose, including 1.5mg LDN. See which opioids, medications, and supplements to avoid.